| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 and Type II Variation in the European Union in Early 2027 |
| 28 Aug 2026 |
8-K: Other Events
Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine |
| 13 Aug 2026 |
8-K: Other Events
On August 13, 2026, Cytokinetics, Incorporated (the “Company”) filed a complaint in the United States District Court for the District of Delaware against Bristol-Myers Squibb Company and MyoKardia, Inc. The complaint seeks a declaratory ... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; |
| 27 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The following is a brief description of each matter voted upon at the Company’s Annual Meeting of Stockholders on May 27, 2026 (the “Annual Meeting”), as well as the number of votes cast for or against each matter and the number of abste... |
| 08 May 2026 |
8-K: Other Events
Cytokinetics, Incorporated, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwr... |
| 05 May 2026 |
8-K: Other Events
Forward-Looking Statements This presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-lo... |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
U.S. Launch of MYQORZO® (aficamten) in Late January Met with Strong Demand; |
| 24 Feb 2026 |
8-K: Results of Operations and Financial Condition
MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; |
| 17 Feb 2026 |
8-K: Other Events
Cytokinetics, Incorporated today announced that the European Commission has approved MYQORZO® (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive... |
| 19 Dec 2025 |
8-K: Other Events
On December 19, 2025, Cytokinetics, Incorporated announced that the U.S. Food and Drug Administration ("FDA") has approved MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, 20 mg tablets, for the treatment of adults with symptomatic obstructive ... |
| 12 Dec 2025 |
8-K: Other Events
On December 12, 2025, Cytokinetics, Incorporated ("Cytokinetics" or the "Company") announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing a... |
| 14 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On November 13, 2025, Cytokinetics, Incorporated (the “Company”) entered into an employment offer letter (the “Offer Letter”) with Jeffrey J. Hessekiel, pursuant to which Mr. Hessekiel has agreed to serve as the Company’s Executive Vice ... |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
Interactions with FDA Progressing Towards December 26, 2025 PDUFA Date for Aficamten; U.S. Commercial Launch Preparations on Track |
| 22 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
INDENTURE, dated as of September 19, 2025, between Cytokinetics, Incorporated, a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). |
| 16 Sep 2025 |
8-K: Other Events
On September 15, 2025, Cytokinetics, Incorporated (the “Company”) participated in a Late Cycle Meeting with the United States Food and Drug Administration (“FDA”) in connection with the Company’s New Drug Application (“NDA”) for aficamte... |
| 03 Sep 2025 |
8-K: Other Events
Improves Cardiac Structure and Function Compared to Metoprolol; |
| 02 Sep 2025 |
8-K: Other Events
Positive Trial Demonstrates Superiority of Aficamten to Standard-of-Care Beta-Blocker Metoprolol |
| 20 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On August 19, 2025, (the “Effective Date”), the Board of Directors (the “Board”) of Cytokinetics, Incorporated (the “Company”) appointed, upon the recommendation of the Nominating and Governance Committee of the Board, James M. Daly to f... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Regulatory Reviews of Aficamten for Obstructive HCM Progressing in U.S., E.U. and China; |
Loading...